about
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritisMuscle biopsy features of idiopathic inflammatory myopathies and differential diagnosisThe antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapyAnti-inflammatory and immunosuppressive drugs and reproductionInternational and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.Recombinant anti-P protein autoantibodies isolated from a human autoimmune library: reactivity, specificity and epitope recognition.The periprosthetic capsule and connective tissue diseases: a piece in the puzzle of autoimmune/autoinflammatory syndrome induced by adjuvants.Antiphospholipid antibodies in mixed connective tissue disease.Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients.[Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data]Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeMyofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation.Polymyositis, dermatomyositis and malignancy: a further intriguing link.EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.SLE diagnosis and treatment: when early is early.European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studiesOverlap connective tissue disease syndromes.Autoantibodies to ribosomal P proteins in systemic lupus erythematosus.Intravenous immunoglobulins control scleromyxoedemaClinical implications of autoantibody screening in patients with autoimmune myositis.Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigenNovel aspects of Sjögren's syndrome in 2012.The clinical features, diagnosis and classification of dermatomyositis.Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active diseaseIn-/off-label use of biologic therapy in systemic lupus erythematosus.Drugs in induction and treatment of idiopathic inflammatory myopathiesMyositis autoantibodies and clinical phenotypes.Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation.Protective molecules and their cognate antibodies: new players in autoimmunityAnti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodiesRisk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosusAnti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosusAnti-signal recognition particle autoantibodies: marker of a necrotising myopathy.Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice.Pregnancy in rare autoimmune rheumatic diseases: UCTD, MCTD, myositis, systemic vasculitis and Beçhet disease.
P50
Q24803670-86C9E2AD-FEAE-4D89-9DD7-AB07905EE3ABQ26991722-838FDCE0-95A1-49EF-B827-EAD38DB2F892Q28194927-5B26A0B7-FB28-4FD8-9648-596FAA171D74Q28218219-56BBFA74-4B97-4488-98E0-EAC50E66140FQ30234696-39FA10A3-B4DD-48BC-A610-06F97B8C8D77Q30926307-531D957A-1836-47FA-A619-830178C32B61Q33354622-0C4A91BE-661A-434A-B47E-B728D5A25419Q33365768-F30708F4-3BDF-41A5-8993-28526AECB17FQ33366716-3AC861D9-6FF4-4B4B-A7F5-505B94727C89Q33394453-A15BBFC2-A1A7-4E72-8514-E9D15045F19AQ33530317-9B054AF0-8023-4DE9-83DD-41101440F25DQ33566129-4AFC4028-DF9A-462E-AEE9-639105182BFDQ33698040-DAC6A258-6A49-412F-A573-2853E4D47FBEQ33731711-13BBA8BE-5C40-4333-8F92-F22F17239537Q33923345-F09375FB-105D-478E-A049-82522005213FQ34089323-3431D751-5C13-410B-A7A6-0D2F9A27D7C8Q34132211-5C2E0F77-5EC8-43DB-BA37-E1DD1BFBAB4EQ34135709-564A4EF5-EFE1-44EF-A519-84056902CE0CQ34187282-1FCB826F-ED00-44F4-B44B-2D7E329E0ABFQ34284779-3FAEE0DE-B89F-4F74-A518-BEEF2500BF9EQ34454056-E1764EDF-1BB2-413D-BC82-B46492CD5888Q34486310-A60C5C55-E81F-4D60-9100-A24936C1B557Q34537296-38C82DCB-1F65-4AA3-AC61-F0681063ED73Q34564174-4CA019CA-3A12-420F-8561-7C64E2C528D7Q34650103-D24B7A1C-2A2B-483E-96F7-D81EDD72700BQ34659254-E0BCDED2-C324-4EAB-9048-21C0B88F320CQ34660000-6D7CD776-A70F-46AB-837C-48CBC19783F1Q34949611-36720997-A36C-4675-BE9A-177070F21092Q35094536-48826495-816E-410E-A5CD-AC27460DEB58Q35281940-D0209097-3FF8-4449-9E0C-41472143DD48Q35281962-480E9C56-0D20-486C-AA42-765605C716ABQ35281980-1A3FF760-D0B3-4E4F-95E0-16306CDC6120Q35309510-62AB4D84-675E-4D75-A5C2-9877925D596DQ35549039-2F81BD27-D1FE-44BC-A2CD-C3159D6DEFDFQ35552185-C6893E4F-6567-429B-A78A-EF51A97B015FQ35555094-4DE3538D-01A9-4B06-B325-C019A8E968B2Q35636994-B832E5E5-050E-4C08-A9CC-4E43D491D629Q35638565-CC35FB0E-03B5-48EE-B0BF-9286FA626F58Q35642120-F045E704-76BB-4AF6-A0D9-576C9E1E7C80Q35918373-7E3E9B1F-8DFC-4D28-B914-AF368A3B636D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrea Doria
@ast
Andrea Doria
@en
Andrea Doria
@es
type
label
Andrea Doria
@ast
Andrea Doria
@en
Andrea Doria
@es
prefLabel
Andrea Doria
@ast
Andrea Doria
@en
Andrea Doria
@es
P106
P1153
36641520900
P31
P496
0000-0003-0548-4983